User profiles for Richard Messmann
 | Richard MessmannVerified email at amgen.com Cited by 3967 |
[HTML][HTML] Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer
…, E Kpamegan, G Gericke, RA Messmann… - … England Journal of …, 2021 - Mass Medical Soc
Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …
[PDF][PDF] Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms
EA Sausville, SG Arbuck, R Messmann… - Journal of Clinical …, 2001 - researchgate.net
Purpose: To define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of
the novel protein kinase inhibitor, UCN-01 (7-hydroxystaurosporine), administered as a 72-…
the novel protein kinase inhibitor, UCN-01 (7-hydroxystaurosporine), administered as a 72-…
[PDF][PDF] PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in …
…, CP Leamon, DE Morgenstern, RA Messmann - J Clin …, 2013 - researchgate.net
Purpose Vintafolide (EC145) is a folic acid–desacetylvinblastine conjugate that binds to the
folate receptor (FR), which is expressed on the majority of epithelial ovarian cancers. This …
folate receptor (FR), which is expressed on the majority of epithelial ovarian cancers. This …
Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor–positive solid tumors
…, DE Morgenstern, RA Messmann… - Journal of Nuclear …, 2008 - Soc Nuclear Med
99m Tc-EC20 is a folate receptor (FR)–targeted imaging agent consisting of the vitamin folate
conjugated to 99m Tc. FR is expressed on a variety of epithelial cancers, with advanced …
conjugated to 99m Tc. FR is expressed on a variety of epithelial cancers, with advanced …
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).
…, M Desilvio, EE Kpamegan, G Gericke, RA Messmann… - 2021 - ascopubs.org
LBA4 Background: Despite recent therapeutic advances, metastatic castration-resistant
prostate cancer (mCRPC) remains invariably fatal. Prostate-specific membrane antigen (PSMA) …
prostate cancer (mCRPC) remains invariably fatal. Prostate-specific membrane antigen (PSMA) …
[HTML][HTML] Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
F Shah, D Logsdon, RA Messmann… - NPJ precision …, 2017 - nature.com
Reduction-oxidation factor 1-apurinic/apyrimidinic endonuclease (Ref-1/APE1) is a critical
node in tumor cells, both as a redox regulator of transcription factor activation and as part of …
node in tumor cells, both as a redox regulator of transcription factor activation and as part of …
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory …
RA Messmann, ES Vitetta, D Headlee… - Clinical Cancer …, 2000 - AACR
This study used an 8-day continuous infusion regimen of a 1:1 mixture of two immunotoxins (ITs)
prepared from deglycosylated ricin A chain (dgA)conjugated to monoclonal antibodies …
prepared from deglycosylated ricin A chain (dgA)conjugated to monoclonal antibodies …
[HTML][HTML] Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors
…, PJ Klein, CP Leamon, RA Messmann… - Journal of clinical …, 2012 - ncbi.nlm.nih.gov
Purpose EC145 (vintafolide), a conjugate of folic acid and the vinca alkaloid desacetylvinblastine
hydrazide (DAVLBH), is a ligand for the folate receptor (FR), with activity against FR-…
hydrazide (DAVLBH), is a ligand for the folate receptor (FR), with activity against FR-…
[HTML][HTML] A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
…, MP Sooch, MJ Woolliscroft, RA Messmann - Cancer chemotherapy …, 2014 - Springer
Purpose Maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics were
assessed in this phase 1 study of PNT2258, a BCL-2-targeted liposomal formulation of a 24-…
assessed in this phase 1 study of PNT2258, a BCL-2-targeted liposomal formulation of a 24-…
The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease
…, S Gampala, L Armstrong, RA Messmann… - Drug Discovery …, 2021 - Elsevier
Highlights • APE1 protein repairs small base lesions in the DNA base excision repair pathway.
• APE1 converts oxidized inactive transcription factors to a reduced and active state. • …
• APE1 converts oxidized inactive transcription factors to a reduced and active state. • …